logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Enzalutamide in addition to androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer

< Back

Enzalutamide in addition to androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer

Drugs

Cancer and Palliative Care

January 2019


Enzalutamide in addition to androgen deprivation therapy (ADT) is in clinical development for the treatment of metastatic hormone-sensitive prostate cancer. Prostate cancer is the second most common cancer in the UK and is classified into localised (confined to the prostate gland), locally advanced (spread outside the capsule of the prostate gland) and advanced (spread to other parts of the body). Advanced prostate cancer that still responds to ADT is identified as metastatic hormone-sensitive prostate cancer. Current treatment options at this stage often involve either ADT alone (surgical removal of the testes or hormone therapy) or ADT in combination with chemotherapy.
Enzalutamide is an oral capsule that works by blocking the androgen receptor to modify the effects of androgens on the prostate, stopping the growth of the cancer cells. Enzalutamide in addition to ADT may offer an alternative option for people that cannot receive or do not respond to chemotherapy plus ADT. If licensed, enzalutamide in addition to ADT will increase the treatment options available for patients with metastatic hormone-sensitive prostate cancer.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts